Regulation - Lucentis

Filter

Current filters:

Lucentis

Popular Filters

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

16-06-2014

Steven Bradshaw, a UK-based drug policy expert and former ophthalmologist, is disappointed at the news…

AvastinEuropeItalyLucentisOphthalmicsPharmaceuticalRegulationRoche

Novartis gets fourth indication, DME, for Lucentis in Japan

24-02-2014

Swiss drug major Novartis says it has received approval from Japanese regulatory bodies for a fourth…

Asia-PacificJapanLucentisNovartisOphthalmicsPharmaceuticalRegulation

NICE final guidance gives green light to Lucentis for CNV

NICE final guidance gives green light to Lucentis for CNV

27-11-2013

The UK’s National Institute for Health and Care Excellence (NICE) has issued final guidance recommending…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Regulator backs Inlyta, Lucentis and Xtandi for NHS Scotland, but not Bosulif

12-11-2013

The Scottish Medicines Consortium (SMC) revealed this morning (November 12) that it has accepted US drug…

Astellas PharmaBosulifEuropeInlytaLucentisNovartisOncologyOphthalmicsPfizerPharmaceuticalRegulationXtandi

NICE gives green light to Novartis’ Lucentis for eye condition

NICE gives green light to Novartis’ Lucentis for eye condition

25-10-2013

NICE has issued final draft guidance recommending Novartis' Lucentis for people with pathological myopia.

EuropeLucentisNovartisOphthalmicsPharmaceuticalRegulation

Novartis' Lucentis first drug approved in EU for myopic choroidal neovascularization

05-07-2013

The European Commission has granted Swiss drug major Novartis (NOVN: VX) a new indication for Lucentis…

EuropeLucentisNovartisOphthalmicsPharmaceuticalRegulation

NICE "green light" for Bayer's Eylea as a treatment for wet AMD

31-05-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (May 31)…

BayerEuropeEyleaLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

NICE rejects Avastin for ovarian cancer, but backs Lucentis for RVO

22-05-2013

The UK's drugs watchdog the National Institute for Health and Care Excellence (NICE) has this morning…

AvastinBiotechnologyEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPricingRegulationRoche

UK's NICE backs use of Novartis' Lucentis for diabetic macular edema

27-02-2013

Reversing an earlier negative opinion, in a final guidance issued today (February 27), the UK drugs watchdog…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

UK's NICE final guidance on Novartis' Lucentis for diabetic macular edema positive

03-01-2013

In final draft guidance issued today (4 January), the UK's drug watchdog the National Institute for Health…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME

11-12-2012

Japanese drug major Eisai's (TYO: 4523) Fycompa (perampanel), a treatment for partial epilepsy, is now…

EisaiEuropeFycompaLucentisNeurologicalNovartisPharmaceuticalPricingRegulation

UK's NICE draft guidance backs NHS use of Lucentis in DME

05-10-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in new draft guidance…

BiotechnologyEuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Safety of Novartis' Lucentis in VI-DME confirmed with new data; efficacy in CNV

06-09-2012

New data revealed yesterday by Swiss drug major Novartis (NOVN: VX) showed that Lucentis (ranibizumab)…

DiabetesLucentisNovartisOphthalmicsPharmaceuticalRegulationResearchRoche

Roche gains FDA approval for Lucentis in diabetic macular edema

13-08-2012

US biotech firm Genentech, a subsidiary of Swiss drug major Roche (ROG: SIX) announced on Friday that…

GenentechLucentisNorth AmericaOphthalmicsPharmaceuticalRegulationRoche

Genentech gains FDA panel backing for Lucentis to treat DME

30-07-2012

US biotech firm Genentech, a subsidiary of Swiss drug major Roche (ROG: SIX), revealed last week that…

BiotechnologyGenentechLucentisNorth AmericaOphthalmicsPharmaceuticalRegulationRoche

Drug approval and launch for Novartis in China, where Quintiles expands

18-01-2012

Swiss drug major Novartis (NOVN: VX) says it has received regulatory approval in China from the State…

Asia-PacificDiabetesGalvusLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalQuintilesRegulationResearch

Final NICE “No” for Novartis’ Lucentis in diabetic macular edema treatment

30-11-2011

The National Institute for Health and Clinical Excellence (NICE), in final guidance issued today (November…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

UK’s NICE gives preliminary “no” to Novartis’ Lucentis for macular edema

24-11-2011

In preliminary recommendations published today (November) 24 by the UK drugs watchdog the National Institute…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Back to top